BIOLASE Comments on $5 Million Private Placement With Oracle Investment Management, Inc.

BIOLASE Comments on $5 Million Private Placement With Oracle Investment 
Management, Inc. 
Company Use of Capital Raise Is to Pay Down Credit Facilities With
Comerica Bank Which Totaled Approximately $4.6 Million at December
31, 2013 
IRVINE, CA -- (Marketwired) -- 02/12/14 --  BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading manufacturer and distributor of dental
lasers, including the Company's proprietary WaterLase, and a pioneer
in laser surgery in other medical specialties, as well as a
distributor of digital radiography and Galaxy CAD/CAM systems for
dentistry, today commented on its recent $5 million private placement
with Oracle Partners LP. 
Chairman and CEO Federico Pignatelli said, "This private placement
will allow BIOLASE to pay down its credit facilities with Comerica
Bank, which at December 31, 2013, amounted to $4.6 million. This
capital infusion is substantially strengthening our balance sheet." 
"Such improved capital structure will help us create the conditions
necessary for 2014 to be a year of resumed growth, and we expect that
such growth will bring us to sustained profitability. The placement
comes at a very exciting time in our corporate development. BIOLASE
is moving beyond the core dental applications of our laser technology
to other medical applications as evidenced by the development of our
DRAGON(TM) technology. 
"DRAGON(TM) combines our proprietary WaterLase energy with a diode
laser, first and a unique approach for an Erbium based laser, to
deliver simultaneous and intertwined laser energy from the same
delivery system. When product development will be completed,
clinicians could be able to use it for: 


 
--  Wound healing for burns and trauma;
--  Wound healing for chronic wounds;
--  Otolaryngology ("ENT") surgery;
--  Ophthalmology."

  
Mr. Pignatelli concluded, "With a stronger balance sheet and the
development of DRAGON(TM), BIOLASE is continuing its drive to cutting
edge laser technology along with sustained revenue growth and
profitability." 
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment and CAD/CAM intraoral scanners and
in-office milling machines; products that are focused on technologies
that advance the practice of dentistry and medicine. The Company's
proprietary laser products incorporate approximately 300 patented and
patent-pending technologies designed to provide biologically
clinically superior performance with less pain and faster recovery
times. Its innovative products provide cutting-edge technology at
competitive prices to deliver the best results for dentists and
patients. BIOLASE's principal products are revolutionary dental laser
systems that perform a broad range of dental procedures, including
cosmetic and complex surgical applications, and a full line of dental
imaging equipment. BIOLASE has sold more than 24,800 lasers. Other
laser products under development address ophthalmology and other
medical and consumer markets. 
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at www.biolase.com, Facebook at
www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc,
Pinterest at www.pinterest.com/biolase, LinkedIn at
www.linkedin.com/company/biolase, Google+ at
www.google.com/+BIOLASEIrvine, Instagram at
www.instagram.com/biolaseinc and YouTube at
www.youtube.com/biolasevideos. 
BIOLASE(R), WaterLase(R), and GALAXY BioMill(TM) are registered
trademarks or trademarks of BIOLASE, Inc. 
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995
 Statements contained in this press release that refer to
BIOLASE's estimated or anticipated future results or other
non-historical facts are forward-looking statements, as are any
statements in this press release concerning prospects related to
BIOLASE's strategic initiatives, product introductions and
anticipated financial performance. Forward-looking statements can
also be identified through the use of words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates,"
"may," "will," and variations of these words or similar expressions.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which reflect BIOLASE's current
perspective of existing trends and information and speak only as of
the date of this release. Actual results may differ materially from
BIOLASE's current expectations depending upon a number of factors
affecting BIOLASE's business. These factors include, among others,
adverse changes in general economic and market conditions,
competitive factors including but not limited to pricing pressures
and new product introductions, uncertainty of customer acceptance of
new product offerings and market changes, risks associated with
managing the growth of the business, and those other risks and
uncertainties that may be detailed, from time-to-time, in BIOLASE's
reports filed with the SEC. BIOLASE does not undertake any
responsibility to revise or update any forward-looking statements
contained herein. 
For further information, please contact: 
Michael Porter
Porter, LeVay & Rose, Inc. 
212-564-4700 
 
 
Press spacebar to pause and continue. Press esc to stop.